Weaver C. Barksdale & Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-739	Closed	-$2K	–	526
2017 Q2	$2K	Hold	739	–	–	﹤0.01%	493
2017 Q1	$2K	Hold	739	–	–	﹤0.01%	492
2016 Q4	$2K	Hold	739	–	–	﹤0.01%	496
2016 Q3	$2K	Hold	739	–	–	﹤0.01%	495
2016 Q2	$2K	Hold	739	–	–	﹤0.01%	484
2016 Q1	$2K	Hold	739	–	–	﹤0.01%	507
2015 Q4	$3K	Hold	739	–	–	﹤0.01%	469
2015 Q3	$4K	Hold	739	–	–	﹤0.01%	432
2015 Q2	$5K	Hold	739	–	–	﹤0.01%	407
2015 Q1	$5K	Hold	739	–	–	﹤0.01%	406
2014 Q4	$6K	Buy	739 +409	+124%	+$3.24K	﹤0.01%	367
2014 Q3	$2K	Buy	+330	New	+$3.06K	﹤0.01%	512
2013 Q4	–	Sell	-170	Closed	-$1K	–	577
2013 Q3	$1K	Hold	170	–	–	﹤0.01%	549
2013 Q2	$1K	Buy	+170	New	+$1.33K	﹤0.01%	547

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Weaver C. Barksdale & Associates's PDLI Position: Q3 2017 in Review

Weaver C. Barksdale & Associates sold out of PDL BioPharma, Inc. (PDLI) in Q3 2017, closing a stake of 739 shares — an estimated $2K sold.

Weaver C. Barksdale & Associates first reported a position in PDLI in Q2 2013 and held it in 14 quarters. The position peaked at $6K in Q4 2014. 186 funds tracked by Wall St. Rank hold PDLI as of Q3 2017.

Weaver C. Barksdale & Associates reported no remaining PDL BioPharma, Inc. position as of Q3 2017 after selling out during the quarter.
Weaver C. Barksdale & Associates sold 739 PDL BioPharma, Inc. shares in Q3 2017, an estimated $2K.
Weaver C. Barksdale & Associates first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 14 quarters.
Weaver C. Barksdale & Associates's PDL BioPharma, Inc. position peaked at $6K in Q4 2014.
186 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q3 2017, filed 12 Oct 2017.